Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES

v3.22.1
ACCRUED EXPENSES
 3 Months Ended
Mar. 31, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

10. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

 

 

March 31,
2022

 

 

December 31,
2021

 

 

 

 

 

 

 

 

Accrued clinical operations and trials costs

 

$

2,132,865

 

 

$

5,435,464

 

Accrued product development costs

 

 

7,788

 

 

 

203,676

 

Accrued compensation

 

 

1,549,871

 

 

 

2,715,368

 

Accrued administrative costs

 

 

1,198,396

 

 

 

1,213,699

 

Accrued interest

 

 

607,486

 

 

 

525,105

 

Total

 

$

5,496,406

 

 

$

10,093,312